- Combined post- and precapillary pulmonary hypertension in the setting of heart failure with preserved ejection fraction (CpcPH–HFpEF) is a highly morbid condition with no currently approved treatments.
- Sotatercept, an activin signaling inhibitor, has emerged as a promising new therapy for pre-capillary pulmonary hypertension (PH); however, little is known about its effects in CpcPH-HFpEF, including its effects on cardiac structure and function.
- In the Phase II CADENCE trial, sotatercept demonstrated a significant improvement in numerous echocardiographic markers of both right and left heart size and right ventricular afterload, potentially overcoming the traditional risk of left-sided congestion observed with most pulmonary vasodilator therapies.
While pre-capillary pulmonary hypertension (PH) has many established pharmacological interventions, there are comparatively far fewer available options for those with concomitant post-capillary PH, particularly in the setting of heart failure with preserved ejection fraction (CpcPH-HFpEF). Sotatercept acts on the activin signaling pathway and has recently demonstrated significant reduction in time to death or clinical worsening in pre-capillary PH, likely by combating a series of proinflammatory and profibrotic pathways and encouraging favorable vascular remodeling. These pathways are also operant in CpcPH-HFpEF, and preliminary evidence from the Phase II CADENCE trial have demonstrated a reduction in pulmonary vascular resistance in CpcPH-HFpEF patients treated with sotatercept over 24 weeks. In a breaking presentation at the 2026 American Heart Association (AHA) Scientific Sessions on November 8th, Dr. Ryan Tedford and his team presented a secondary, echocardiographic analysis of these findings, entitled “Effects of Sotatercept on Cardiac Structure and Function: Analysis of the CADENCE Study.”
In the CADENCE (NCT04945460) trial, patients were randomized 1:1:1 to sotatercept 0.3 mg/kg, sotatercept titrated from 0.3 to 0.7 mg/kg, or placebo, administered subcutaneously every 3 weeks for 24 weeks. A total of 164 patients with CpcPH-HFpEF were enrolled; of these, 109 received sotatercept (n=54 in the 0.3 mg/kg arm and n=55 in the 0.7 mg/kg arm, but these two groups were pooled for the purpose of this secondary analysis), and 55 were in the placebo group. Eight patients were excluded from this analysis due to missing echocardiographic data.
Sotatercept use was associated with significant reductions in numerous echocardiographic measures of right ventricular (RV) afterload and size, including tricuspid regurgitation (TR) peak velocity (a 72.21cm/s point reduction, 95% CI -95.23 to -49.19; P<0.001) RV end-diastolic area (-3.93cm2, 95% CI -6.78 to -1.08; P=0.005), and end-systolic area (-3.04cm2, 95% CI -5.12 to -0.96; P=0.002). There were no differences observed in any other traditional measures of RV function, including fractional area change or tricuspid annular plane systolic excursion. However, TR severity did improve with sotatercept (P=0.002), but not with placebo. Sotatercept use also modestly improved left atrial volume index (-5.41ml/m2, 95% CI -10.16 to -0.66; P=0.023) and left ventricular end-diastolic diameter (-0.25cm, 95% CI -0.50 to -0.01; P=0.030). There were no differences in left ventricular mass index or myocardial volume index, but the reduction in eccentricity index (-0.21, 95% CI -0.36 to -0.06; P=0.002) suggested a potential reduction in ventricular interaction.
Overall, sotatercept use in CpcPH-HFpEF was associated with a significant reduction in measures of RV afterload, right heart structure, left-sided remodeling, and ventricular interaction, concordant with the reduction in left-sided filling pressures observed in the original CADENCE analyses. These findings suggest that sotatercept may improve pulmonary hypertension and right ventricular overload without a concomitant rise in left-sided filling pressures, potentially overcoming the traditional risk observed with pulmonary vasodilators particularly in patients with HFpEF. This simultaneous improvement in right- and left-sided volume may be due to the effects of activin pathway inhibition of the compliance of the pulmonary venous and subsequently left atrial compartment.
